MétaCan
Menu
Back to cohort
Record W4409774343 · doi:10.1080/14796694.2025.2489319

Order of treatment with ALK inhibitors and its effect on people with lung cancer in the real world: a plain language summary

2025· article· en· W4409774343 on OpenAlexafffund
Jessica R. Bauman, Geoffrey Liu, Isabel R. Preeshagul, Barbara Melosky, Devin Abrahami, Benjamin Li, Despina Thomaidou, Stan Krulewicz, Martin Rupp

Bibliographic record

VenueFuture Oncology · 2025
Typearticle
Languageen
FieldMedicine
TopicLung Cancer Treatments and Mutations
Canadian institutionsPfizer (Canada)Princess Margaret Cancer Centre
FundersNational Cancer InstituteCanadian Cancer Society Research InstituteEMD SeronoJazz PharmaceuticalsMemorial Sloan-Kettering Cancer CenterSanofiG1 TherapeuticsAmgenPfizerGenentechAstraZenecaEli Lilly and CompanyBristol-Myers Squibb
KeywordsMedicineLung cancerPlain languageOncologyOrder (exchange)Intensive care medicineInternal medicineLinguistics

Abstract

fetched live from OpenAlex

Plain Language SummaryWhat is this summary about?This is a summary of the results of a recent study. Researchers studied people with ALK-positive advanced non-small cell lung cancer (NSCLC) who were treated with medicines called ALK inhibitors. In the study, researchers looked at the order (or sequence) these medicines were given to people in the real world (not part of a clinical study), and how long the people took each medicine when they were given it as a first or second treatment. Several different ALK inhibitors are approved to treat this type of cancer. Understanding how well diffeent treatment sequences work will help healthcare professionals select the right treatments for their patients.What did this study find?This study used de-identified medical information from 273 patients in the Flatiron database (a collection of information about patients with cancer). This study found that in people who stopped their first ALK inhibitor treatment, about 1 out of 5 (22%) died without receiving a second treatment, and at least half of these people died within 4.0 months of stopping the first treatment. At least half of the people stopped taking their first treatment after 21.9 months and their second treatment after 7.3 months. At least half of the people stopped taking their first and second treatments after 29.4 months. When ALK inhibitors were taken in any sequence during treatment, at least half of the people stopped taking ALK inhibitors after 28.0 months.What do the findings of this study mean?The findings from this study show that not all people who stop taking their first treatment are able to take a second treatment. People take their first treatment for a longer time than their second treatment, highlighting the importance of selecting an effective first treatment option.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-text

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.113
Threshold uncertainty score0.954

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.004
GPT teacher head0.334
Teacher spread0.330 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueFuture OncologySame topicLung Cancer Treatments and MutationsFrench-language works237,207